AndroGel Monitoring for Adults (30 to 49): Lab Schedule, Safety Checks, and What to Track

What does the label say to check, and when?

This page rests on the label for generic testosterone gel 1% (Teva), which is a different label from the one for AndroGel 1.62% [1]. In its warnings, the label says to monitor serum testosterone, PSA, hemoglobin, hematocrit, liver function tests and lipid concentrations periodically [1].

Hematocrit is the only one with its own timetable. The label says to check it before starting treatment, re-evaluate it 3 to 6 months after starting, and then annually [1]. If hematocrit becomes elevated, it says to stop therapy until hematocrit decreases to an acceptable concentration, and it notes that an increase in red blood cell mass may increase the risk of thromboembolic events [1]. The warning does not name a numeric cutoff.

Blood pressure is handled separately: the label says to monitor it periodically, especially in men with hypertension, and that the gel is not recommended for men with uncontrolled hypertension [1].

Before the first dose

The label says to confirm the diagnosis before treatment starts, with morning serum testosterone measured on at least two separate days and both results below the normal range [1]. The Endocrine Society guideline takes the same position, diagnosing hypogonadism only in men with symptoms and consistently low morning total testosterone, confirmed by repeat measurement [2].

The label's own baseline instruction is a hematocrit check before treatment, and it asks for blood pressure to be measured periodically [1]. The other items on the periodic list, PSA and lipids among them, are described as periodic rather than tied to a specific visit [1].

On regulatory status, the gel 1% label still carries the limitation of use that safety and efficacy in age-related hypogonadism have not been established, and FDA asked in June 2026 for that limitation to be removed from testosterone labels [3][1]. Testosterone gel 1% also contains testosterone, a Schedule III controlled substance [1].

The first 3 to 6 months

The 3-to-6-month hematocrit recheck is the one timed lab on the label [1]. The label also reports PSA data from the gel 1% trial program.

In the 180-day phase 3 study, mean PSA rose 0.26 ng/mL, a statistically significant change [1]. PSA was then measured every 6 months in 162 men in a 3-year extension study, with no additional statistically significant mean increase from 6 through 36 months; the overall mean change from month 6 to 36 was 0.11 ng/mL [1]. Individual patients still moved: about 18% had PSA increases, and 29 patients (18%) met a protocol criterion of more than twice baseline or any single PSA above 6 ng/mL [1]. Most of those (25 of 29) met it by doubling, and in 22 of the 25 the highest value was still under 2 ng/mL [1]. The first qualifying rise appeared at or before month 12 in 23 of the 29 [1]. Four men went above 6 ng/mL, and prostate cancer was found on biopsy in two of them [1].

The label's instruction for prostate safety is to monitor men with benign prostatic hyperplasia for worsening symptoms and to evaluate patients for prostate cancer before and during treatment [1].

Hematocrit: what the numbers look like

In a network meta-analysis of 29 placebo-controlled randomized trials (3,393 men), testosterone gel raised mean hematocrit by 3.0% (95% CI 1.8 to 4.3) versus placebo, while intramuscular enanthate or cypionate raised it by 4.0% (95% CI 2.9 to 5.1) [4].

A retrospective review of 178 hypogonadal men followed for 3 years found erythrocytosis (hematocrit above 50%) in 12.8% of men on gels, 35.1% on pellets and 66.7% on injectable testosterone; the injection group was younger and started with higher hematocrit, and the study was not randomized [5]. A review of the erythrocytosis literature put the risk of hematocrit above 0.52 at 315% higher in men on testosterone than in controls, with all formulations raising hemoglobin and hematocrit and injectables raising them most [6].

The label warns that increased red blood cell mass may increase the risk of thromboembolic events, and it separately reports venous thromboembolism from the TRAVERSE trial, which tested 1.62% testosterone gel [1][7]. The label reports venous thromboembolism in that trial at 1.7% versus 1.2% with placebo, including deep vein thrombosis at 0.6% versus 0.5% and pulmonary embolism at 0.9% versus 0.5% [1]. The label says to evaluate patients who report pain, edema, warmth and erythema in the lower extremity for DVT and those with acute shortness of breath for PE, and to discontinue treatment and begin workup if a venous thromboembolic event is suspected [1].

Blood pressure and heart risk

The label says testosterone gel 1% can increase blood pressure, which can increase cardiovascular risk over time [1]. In an ambulatory monitoring study, the mean systolic/diastolic rise was 1.9/1.3 mm Hg from baseline after 16 weeks, and 3.0/2.2 mm Hg in patients with hypertension on antihypertensive therapy [1].

TRAVERSE, the large cardiovascular outcome trial, used daily 1.62% testosterone gel in 5,246 men aged 45 to 80 with existing or high cardiovascular risk [7]. Major adverse cardiovascular events occurred in 7.0% on testosterone and 7.3% on placebo, hazard ratio 0.96 (95% CI 0.78 to 1.17), meeting noninferiority over a mean follow-up of 33 months [7]. Mean systolic pressure rose 1.0 mm Hg on gel versus a 0.5 mm Hg fall on placebo at 36 months, a 1.5 mm Hg between-group difference [1].

TRAVERSE enrolled men aged 45 to 80, so a man in his 30s was not represented [7]. FDA's February 2025 class-wide labeling action called for TRAVERSE results to be added to testosterone labels and for a blood pressure warning on products lacking one, after ambulatory monitoring confirmed a blood pressure increase with all testosterone products [8].

Testosterone levels and dose titration

For testosterone gel 1%, the label gives a starting dose of 50 mg once daily in the morning, applied to clean, dry, intact skin of the shoulders, upper arms and/or abdomen [1]. It says that if serum testosterone is below the normal range, the daily dose may go from 50 to 75 mg and from 75 to 100 mg; if it exceeds the normal range, the dose may be decreased, and if it consistently exceeds the normal range at 50 mg, therapy should be discontinued [1]. The application site and dose of gel 1% are not substitutable with other topical testosterone products [1].

TRAVERSE adjusted the 1.62% gel dose to keep testosterone between 350 and 750 ng/dL [7].

Fertility

The label states plainly that exogenous administration of androgens may lead to azoospermia [1], and the Endocrine Society guideline recommends against starting testosterone therapy in men planning fertility in the near term [2].

How often sperm return after stopping is known mainly from hormonal male contraception research. An integrated analysis of 30 studies in 1,549 healthy men with normal testosterone on androgen or androgen-progestin regimens found a median of 3.4 months for sperm concentration to recover to 20 million/mL, with 67% recovered by 6 months, 90% by 12 months, 96% by 16 months and 100% by 24 months [9]. Recovery was faster with shorter-acting testosterone, shorter treatment, older age and a higher baseline sperm count [9].

For men who develop azoospermia or severe oligospermia on testosterone, a case series of 49 men treated with hCG 3,000 units subcutaneously every other day plus clomiphene, tamoxifen, anastrozole or recombinant FSH reported return or improvement of spermatogenesis in 47 (95.9%), at an average of 4.6 months and a mean first sperm density of 22.6 million/mL [10]. In a separate series of 66 men, 70% reached a total motile count above 5 million within 12 months of stopping testosterone and starting high-dose hCG plus a selective estrogen receptor modulator; older age and longer testosterone use slowed recovery [11].

Lipids, liver, glucose and clotting labs

Lipids and liver function tests are on the label's periodic monitoring list [1]. The label notes that androgens may decrease blood glucose and therefore insulin requirements, and that changes in insulin sensitivity or glycemic control may occur in patients on androgens [1].

Two interactions change what the label asks to monitor. Androgens may change anticoagulant activity, so the label recommends more frequent INR and prothrombin time monitoring, especially at the initiation and termination of androgen therapy [1]. Testosterone with ACTH or corticosteroids may increase fluid retention, and the label says to use caution, particularly in patients with cardiac, renal or hepatic disease [1].

Secondary exposure at home

The boxed warning on testosterone gel concerns secondary exposure of other people. It says virilization has been reported in children secondarily exposed to testosterone gel, and children should avoid contact with unwashed or unclothed application sites [1]. Reported signs include enlargement of the penis or clitoris, pubic hair, increased erections and libido, aggressive behavior and advanced bone age; in most cases these regressed once exposure was removed, but in a few, enlarged genitalia did not fully return to age-appropriate size and bone age stayed modestly advanced [1]. The label says the gel should be promptly discontinued until the cause of virilization is identified [1].

The label's schedule at a glance

• Before starting: morning serum testosterone on at least two separate days, both below the normal range, and a hematocrit [1].
• 3 to 6 months: the hematocrit re-evaluation, then annually [1].
• Periodically after that: serum testosterone, PSA, hemoglobin, liver function tests, lipids and blood pressure, with no specific interval named for each [1].
• At any time: the label says to evaluate lower-extremity pain, edema, warmth and erythema for DVT and acute shortness of breath for PE, and to bring signs of virilization in a child or woman exposed to the gel to a physician's attention [1].